Sanofi hires Selexis SA for three cell line development deals

By Gareth Macdonald

- Last updated on GMT


Related tags Biotechnology Cell culture

Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.

The deals – financial terms of which were not disclosed - will see Selecta develop cell lines for a complex recombinant vaccine protein, a bispecific antibody and so-called “naked” antibody lacking any drug element.

Development will utilize Selexis’ SUREtechnology which is used to insert genes into Chinese hamster ovary (CHO) cells and other mammalian cell lines used in biopharmaceutical production.

Robert Meister, head of Corporate Communications at Selexis SA, told us "This research will take place in Selexis’ new lab facility, formerly owned by Merck Serono, in Plan-les-Ouates, Switzerland."

"Selexis cannot disclose how long the work will take, but typically Selexis produces new research cell banks in approximately 14 weeks" he added.

Selexis has similar cell development and technology access deals with ImmuNext, Laboratorios Liomont, Progenics Pharmaceuticals, ASLAN Pharmaceuticals​ and Pieris Pharmaceuticals​.

News of the Sanofi contracts comes months​ after the firm told us it will begin a "major expansion"​ this year.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more